CYMABAY THERAPEUTICS INC's ticker is CBAY and the CUSIP is 23257D103. A total of 115 filers reported holding CYMABAY THERAPEUTICS INC in Q3 2021. The put-call ratio across all filers is 2.01 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2022 | $73,000 | +12.3% | 11,561 | -37.5% | 0.00% | – |
Q3 2022 | $65,000 | -1.5% | 18,511 | -16.8% | 0.00% | – |
Q2 2022 | $66,000 | -10.8% | 22,261 | -5.9% | 0.00% | – |
Q1 2022 | $74,000 | -6.3% | 23,661 | +0.6% | 0.00% | – |
Q4 2021 | $79,000 | -34.2% | 23,511 | -28.0% | 0.00% | – |
Q3 2021 | $120,000 | -19.5% | 32,645 | -5.0% | 0.00% | – |
Q2 2021 | $149,000 | -7.5% | 34,350 | -3.6% | 0.00% | – |
Q1 2021 | $161,000 | -33.7% | 35,625 | -18.7% | 0.00% | – |
Q4 2020 | $243,000 | +6.1% | 43,801 | +38.2% | 0.00% | – |
Q3 2020 | $229,000 | +281.7% | 31,696 | +86.2% | 0.00% | – |
Q2 2020 | $60,000 | -31.0% | 17,021 | +0.0% | 0.00% | – |
Q3 2019 | $87,000 | -28.1% | 17,018 | +0.9% | 0.00% | – |
Q2 2019 | $121,000 | -48.7% | 16,868 | -5.1% | 0.00% | – |
Q1 2019 | $236,000 | +73.5% | 17,779 | +3.3% | 0.00% | – |
Q4 2018 | $136,000 | -20.5% | 17,219 | +11.2% | 0.00% | – |
Q3 2018 | $171,000 | -11.9% | 15,479 | +7.4% | 0.00% | – |
Q2 2018 | $194,000 | -83.1% | 14,419 | -83.7% | 0.00% | -100.0% |
Q1 2018 | $1,151,000 | -25.4% | 88,585 | -47.1% | 0.00% | 0.0% |
Q4 2017 | $1,542,000 | +0.4% | 167,544 | -12.1% | 0.00% | 0.0% |
Q3 2017 | $1,536,000 | – | 190,500 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Saturn V Capital Management LP | 1,629,464 | $14,208,926 | 10.61% |
Lynx1 Capital Management LP | 1,369,927 | $11,945,763 | 9.96% |
Versant Venture Management, LLC | 543,753 | $4,741,526 | 9.88% |
Foresite Capital Management IV, LLC | 1,787,094 | $15,583,460 | 8.09% |
Octagon Capital Advisors LP | 4,570,918 | $39,858,405 | 5.74% |
ACUTA CAPITAL PARTNERS, LLC | 878,500 | $7,660,520 | 5.64% |
TCG Crossover Management, LLC | 3,048,257 | $26,580,801 | 5.18% |
Affinity Asset Advisors, LLC | 1,083,118 | $9,444,789 | 3.12% |
Altium Capital Management LP | 620,000 | $5,406,400 | 3.00% |
Bain Capital Life Sciences Investors, LLC | 2,500,000 | $21,800 | 2.72% |